Conmed (CNMD) Tops Q4 EPS by 11c, provides guidance
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Price: $51.07 -0.6%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Conmed (NYSE: CNMD) reported Q4 EPS of $1.43, $0.11 better than the analyst estimate of $1.32. Revenue for the quarter came in at $373.2 million versus the consensus estimate of $366.97 million.
GUIDANCE:
Conmed sees FY2026 EPS of $4.30-$4.45, versus the consensus of $4.42. Conmed sees FY2026 revenue of $1.345-1.375 billion, versus the consensus of $1.369 billion.
For earnings history and earnings-related data on Conmed (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- BofA says CTA Treasury shorts stable, euro short-cover risk rises
- ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
